[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647171":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":24,"locations":33,"responsibleParty":48,"collaborators":12,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":12,"enrollmentInfo":59,"targetDuration":12,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":73,"whyStopped":12,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Region Skane","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard of care including best medical treatment","NO_INTERVENTION","Standard of care including best medical treatment. This may include treatment with OAC, antiplatelet therapy and both or none of the above, depending on the characteristics of the patient and the clinical judgement of the responsible physician.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Video-assisted thoracoscopic closure of the left atrial appendage using a closure device","EXPERIMENTAL","Video-assisted thoracoscopic closure of the left atrial appendage using a closure device and discontinuation of treatment if the patient is treated with OAC. If indicated due to co-morbidities, patients will be prescribed platelet inhibitors instead.",[18],"Procedure: Video-assisted thoracoscopic closure of the left atrial appendage using a closure device and discontinuation of treatment if the patient is treated with OAC",[20],{"type":21,"name":22,"description":16,"armGroupLabels":23,"otherNames":12},"PROCEDURE","Video-assisted thoracoscopic closure of the left atrial appendage using a closure device and discontinuation of treatment if the patient is treated with OAC",[14],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":12,"email":29},"Igor Zindovic, MD, Phd","CONTACT","+4646173300","igor.zindovic@skane.se",{"name":31,"role":27,"phone":28,"phoneExt":12,"email":32},"Karl Teurneau-Hermansson, MD, PhD","Karl.Teurneau-Hermansson@skane.se",[34],{"facility":35,"status":12,"city":36,"state":12,"zip":12,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Skånes universitetssjukhus","Lund","Sweden","SE",{"type":40,"coordinates":41},"Point",[42,43],13.19321,55.70584,{"lat":43,"lon":42},[46],{"name":47,"role":27,"phone":28,"phoneExt":12,"email":29},"Igor Zindovic",{"type":49,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100647171","standalone-thoracoscopic-left-atrial-appendage-closure-versus-medical-therapy-in-atrial-fibrillation-100647171",false,"NCT07705282","Standalone Thoracoscopic Left Atrial Appendage Closure Versus Medical Therapy in Atrial Fibrillation","STELLA-AF","Inclusion Criteria:\n\n1. Age ≥ 18 years and any of criteria 2-3\n2. AF with a CHA2DS2-VA score ≥2 and a HAS-BLED score ≥3 or other clinically significant bleeding condition and ongoing OAC treatment\n3. AF with a CHA2DS2-VA score ≥2 but deemed unfit for OAC by responsible physician due to clinical contraindications (e.g. amyloid angiopathy, previous intracranial haemorrhage or severe gastrointestinal bleeding).\n\nExclusion Criteria:\n\n1. Clinical frailty score ≥5\n2. Indication for OAC other than AF\n3. Indication for dual antiplatelet therapy, if OAC is discontinued\n4. Previous open-heart surgery\n5. Present indication for cardiac surgery\n6. Present indication for ablation for atrial fibrillation\n7. Previous radiation therapy of the chest, due to malignancy\n8. Previous pericarditis or myocarditis\n9. Previous surgery including access to the left pleural space\n10. Documented FEV1\\\u003C70% or other significant pulmonary disease (including but not restricted to fibrosis, pulmonary post-covid syndrome, cystic fibrosis)\n11. Ongoing treatment with corticosteroids or previous treatment for more than 3 consecutive months.\n12. Allergy to contrast media\n13. Patient already included in another interventional clinical trial\n14. Patient listed abroad, which would render them to be lost to follow-up after discharge\n15. Patient does not understand study information given in the local language or, for other reasons, is deemed unfit to participate according to the investigators","ALL","18 Years",{"count":60,"type":61},936,"ESTIMATED","INTERVENTIONAL",[64],"NA","Surgical left atrial appendage closure (LAAC) has been associated with reduced rates of stroke in patients with atrial fibrillation (AF) who have undergone cardiac surgery. In recent time, procedures with catheter-based devices for LAAC have failed to achieve results that would make them considered a safe alternative to oral anticoagulation. Several concerns regarding catheter-based devices have been raised due to their contact with circulating blood, device migration and periprocedural complications. LAAC using an externally placed clip via thoracoscopy would elude some of these concerns and may therefore be a feasible alternative to oral anticoagulation in patients with AF.\n\nThis study aims to assess whether thoracoscopic left atrial appendage closure (TLAAC) is noninferior to medical treatment in patients with AF and an elevated bleeding risk using or being planned to initiate OAC and in those patients with clinical contraindications to oral anticoagulants.",[67,68,69],"ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION","Oral Anticoagulation","Thoracotomy",[71,72],"Left atrial appendage closure","Atrial fibrillation","NOT_YET_RECRUITING","2026-07-10",{"date":76,"type":77},"2026-07-15","ACTUAL",{"date":79,"type":61},"2028-01-01",{"date":81,"type":61},"2032-12-31",{"name":5,"class":6},1]